Immunohistochemical expression of programmed death ligand 1 in squamous cell carcinoma of head and neck

Authors

  • Maria Khan Rehman Medical Institute, Peshawar Pakistan
  • Ayesha Safdar Rehman Medical Institute, Peshawar Pakistan
  • Raazia Mahmood Rehman Medical Institute, Peshawar Pakistan
  • Aisha Jamil Rehman Medical Institute, Peshawar Pakistan
  • Faryal Javaid Rehman Medical Institute, Peshawar Pakistan
  • Iqbal Muhammad Rehman Medical Institute, Peshawar Pakistan

DOI:

https://doi.org/10.55629/pakjpathol.v36i1.890

Abstract

Objective: To assess the immunohistochemical expression and clinicopathological features of Programmed Death Ligand 1 in the head and neck squamous cell carcinoma (HNSCC).

Material and Methods: This Cross-sectional study was conducted at the Histopathology department, Rehman Medical Institute, Peshawar, Sep 2023 to Dec 2024. Patients with histologically confirmed head and neck squamous cell carcinoma were included in the study. Sections from Formalin fixed tissue blocks underwent immunohistochemical staining by PD-L1 antibody followed by analysis. Demographic characteristics and histopathological parameters were recorded.

Results:  Among 92 participants we observed a male predominance with male to female ratio of 3.8:1 with a median (IQR) age of 59.62 (56.85-62) years. The frequency of PD-L1 positivity was observed in 84 (91.3%) patients. The most common site of the tumor was the oral cavity in 56 (60.9%). We observed that lymphovascular and perineural invasion was not significantly associated with PD-L1 positivity. T-stage of the tumors revealed that most tumors had T1 followed by T2 stage, while N-staging revealed most specimens 39 (46.4%) had N1 stage, followed by N0, N3, and N2 stage with a significant correlation to PD-L1 positivity. Tumors with extranodal extension and moderate tumor-infiltrating lymphocytes histologically revealed PD-L1 expression in 30 (35.7%) and 59 (70.2%) with p-0.920 and p-0.239 respectively.

Conclusion:   We conclude that there is a predominance of PD-L1 positivity in HNSCC with a significant correlation between PD-L1 positivity and nodal metastasis. These findings may lead to the development of immunotherapeutic strategies and identification of patients who may benefit from PD-L1 targeted therapies.

Keywords: Immunohistochemistry, PD-L1, Squamous cell carcinoma of head and neck, Immunotherapy

References

Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A. Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma. Med Sci. 2023; 11(2): 42. DOI: https://doi.org/10.3390/medsci11020042

Johnson DE, Burtness B, Leemans CR, Lui VW, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020; 6: 92. DOI: https://doi.org/10.1159/000446117

Sun Z, Sun X, Chen Z, Du J, Wu Y. Head and neck squamous cell carcinoma: Risk factors, molecular alterations, immunology and peptide vaccines. Int J Pept Res Ther. 2022; 28:1-8. DOI: https://doi.org/10.1007/s10989-021-10334-5

Muzaffar J, Bari S, Kirtane K, Chung CH. Recent advances and future directions in clinical management of head and neck squamous cell carcinoma. Cancers. 2021; 13(2): 338. DOI: https://doi.org/10.3390/cancers13020338

Wu J, Wang N. Current progress of anti PD 1/PD-L1 immunotherapy for glioblastoma. Mol Med Rep. 2024; 30(6): 221. DOI: https://doi.org/10.3892/mmr.2024.13344

Unnikrishnan A, Basavaraj V. Evaluation of programmed death-ligand 1 (Pd-L1) expression in head and neck squamous cell carcinoma. Iranian J Pathol. 2023; 18(2): 193-201. DOI:https://doi.org/10.30699/ijp.2023.1988955.3057

Wolfer S, Kunzler A, Foos T, Ernst C, Leha A, Schultze‐Mosgau S. Gender and risk‐taking behaviors influence the clinical presentation of oral squamous cell carcinoma. Clin Exp Dent Res. 2022; 8(1): 141-51. DOI: https://doi.org/10.1002/cre2.523

Chauhan R, Trivedi V, Rani R, Singh U. A study of head and neck cancer patients with reference to tobacco use, gender, and subsite distribution. South Asian J Cancer. 2022; 11(01): 046-51. DOI: https://doi.org/10.1055/s-0041-1740601

Michaelraj MJ, Kuttiappan K, Ramasamy S, Rodrigues FA, Govindaraj S. Demographic profile and risk factors of head-and-neck squamous cell carcinoma in west Tamil Nadu: A cross-sectional observational study. Cancer Res Stat Treat. 2023; 6(2): 215-23. DOI: https://doi.org/10.4103/crst.crst_364_22

Lee JJ, Kunaratnam V, Kim CJ, Pienkowski M, Hueniken K, Sahovaler A, et al. Cigarette smoking cessation, duration of smoking abstinence, and head and neck squamous cell carcinoma prognosis. Cancer. 2023; 129(6): 867-77. DOI: https://doi.org/10.1002/cncr.34620

Malik IS, Asif M, Bashir N, Ara N, Rashid F, Din HU, et al. Frequency of expression of PD-1 and PD-L1 in head and neck squamous cell carcinoma and their association with nodal metastasis: A cross-sectional study. Asian Pac J Cancer Prev. 2022; 23(2): 467-73. https://doi.org/10.31557/APJCP.2022.23.2.467

Paolino G, Pantanowitz L, Barresi V, Pagni F, Munari E, Moretta L, et al. PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity, and therapy. Pathol Res Pract. 2021; 226: 153605. DOI: https://doi.org/10.1016/j.prp.2021.153605

Mishra PS, Sidhu A, Dwivedi G, Mulajker DS, Awasthi S. Determining PD-L1 expression in head and neck squamous cell carcinoma using immunohistochemistry. Indian J Cancer. 2022; 59(4): 474-9. DOI: https://doi.org/10.4103/ijc.IJC_920_19

Kilaru S, Panda SS, Moharana L, Mohapatra D, Mohapatra SS, Panda A, et al. PD-L1 expression in head and neck squamous cell carcinoma and its clinical significance: A prospective observational study from a tertiary care center. J Cancer Res Ther. 2024; 20(1): 46-51. DOI: https://doi.org/10.4103/jcrt.jcrt_1239_22

Lenouvel D, González‐Moles MÁ, Ruiz‐Ávila I, Chamorro‐Santos C, González‐Ruiz L, González‐Ruiz I, et al. Clinicopathological and prognostic significance of PD‐L1 in oral cancer: A preliminary retrospective immunohistochemistry study. Oral Dis. 2021; 27(2): 173-82. DOI: https://doi.org/10.1111/odi.13509

Wusiman D, Guo L, Huang Z, Li Z, Liu S, Ying J, et al. The clinicopathological significance of PD-L1 expression was assessed by the combined positive score (CPS) in head and neck squamous cell carcinoma. Pathol Res Pract. 2022; 236: 153934. DOI: https://doi.org/10.1016/j.prp.2022.153934

Schneider S, Kadletz L, Wiebringhaus R, Kenner L, Selzer E, Füreder T, et al. PD‐1 and PD‐L1 expression in HNSCC primary cancer and related lymph node metastasis–impact on clinical outcome. Histopathology. 2018; 73(4): 573-84. DOI: https://doi.org/10.1111/his.13646

Jiang S, Li X, Huang L, Xu Z, Lin J. Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer. Front Immunol. 2022; 13: 988416. DOI: https://doi.org/10.3389/fimmu.2022.988416

Downloads

Published

20-03-2025

How to Cite

1.
Khan M, Safdar A, Mahmood R, Jamil A, Javaid F, Muhammad I. Immunohistochemical expression of programmed death ligand 1 in squamous cell carcinoma of head and neck. Pak J Pathol [Internet]. 2025 Mar. 20 [cited 2026 Nov. 18];36(1):12-8. Available from: https://www.pakjpath.com/index.php/Pak-J-Pathol/article/view/890